Ultragenyx Pharmaceutical Inc (RARE)
47.24
+1.22
(+2.65%)
USD |
NASDAQ |
Nov 22, 16:00
46.93
-0.31
(-0.66%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Total Liabilities (Quarterly): 1.185B for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.185B |
| June 30, 2024 | 1.186B |
| March 31, 2024 | 1.167B |
| December 31, 2023 | 1.216B |
| September 30, 2023 | 1.206B |
| June 30, 2023 | 1.182B |
| March 31, 2023 | 1.163B |
| December 31, 2022 | 1.193B |
| September 30, 2022 | 1.150B |
| June 30, 2022 | 642.55M |
| March 31, 2022 | 587.60M |
| December 31, 2021 | 599.84M |
| September 30, 2021 | 551.13M |
| June 30, 2021 | 540.27M |
| March 31, 2021 | 543.18M |
| December 31, 2020 | 605.18M |
| September 30, 2020 | 602.19M |
| June 30, 2020 | 618.45M |
| March 31, 2020 | 623.99M |
| December 31, 2019 | 481.73M |
| September 30, 2019 | 152.68M |
| June 30, 2019 | 139.14M |
| March 31, 2019 | 121.03M |
| Date | Value |
|---|---|
| December 31, 2018 | 110.65M |
| September 30, 2018 | 102.55M |
| June 30, 2018 | 102.05M |
| March 31, 2018 | 93.69M |
| December 31, 2017 | 107.30M |
| September 30, 2017 | 69.49M |
| June 30, 2017 | 68.09M |
| March 31, 2017 | 57.34M |
| December 31, 2016 | 66.65M |
| September 30, 2016 | 59.28M |
| June 30, 2016 | 38.06M |
| March 31, 2016 | 34.36M |
| December 31, 2015 | 28.48M |
| September 30, 2015 | 25.37M |
| June 30, 2015 | 23.73M |
| March 31, 2015 | 14.72M |
| December 31, 2014 | 13.02M |
| September 30, 2014 | 11.60M |
| June 30, 2014 | 9.503M |
| March 31, 2014 | 6.993M |
| December 31, 2013 | 9.54M |
| September 30, 2013 | 7.438M |
| December 31, 2012 | 3.976M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
481.73M
Minimum
Dec 2019
1.216B
Maximum
Dec 2023
852.17M
Average
633.27M
Median
Total Liabilities (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 4.173B |
| NovaBay Pharmaceuticals Inc | 2.805M |
| Palatin Technologies Inc | 11.10M |
| iBio Inc | 6.763M |
| Theriva Biologics Inc | 15.47M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.538B |
| Shareholders Equity (Quarterly) | 346.83M |
| Current Ratio | 2.806 |